EUVIMEDEUVIMED entdecken
Klinische Studie

A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis

Elena Vladislavovna Morozova, Maria Vladimirovna Barabanshikova, Ivan Sergeevich Moiseev, Alena Igorevna Shakirova, Ildar Munerovich Barhatov, Inna Edvardovna Ushal, Gennadij Georgievich Rodionov, Sergey Ivanovich Moiseev, Elena Arkadjevna Surkova, Sergey Vladimirovich Lapin, Julia Jurjevna Vlasova, Tatjana Alexandrovna Rudakova und 5 weitere

Acta Haematologica · 2021 · 144 (2) · 158-165

DOI: 10.1159/000506758 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Acta Haematologica, online erschienen am 23.04.2020. Verfasst von Elena Vladislavovna Morozova und 16 weiteren Autor:innen. Beteiligte Einrichtung: R.M. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint-Petersb…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This prospective study evaluated a calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis regimen of ruxolitinib in combination with post-transplant cyclophosphamide (PTCy). Patents and Methods: Twenty patients with primary or secondary myelofibrosis were prospectively enrolled. Reduced intensity conditioning was performed, followed by allogeneic stem cell transplantation from related (n = 7) or unrelated (n = 13) donors. GVHD prophylaxis included only PTCy and ruxolitinib (45 mg) from day–7 to day–2, and 15 mg from day+5 to day+100. This trial was registered at www.clinicaltrials.gov as #NCT02806375.

Results

Primary engraftment was documented in 17 patients. One patient experienced primary graft failure and 2 died before engraftment. Eleven patients demonstrated severe poor graft function (SPGF), which required ruxolitinib dose reduction. The regimen was well tolerated, with grade 3–4 non-haematological toxicity in 30%, viral reactivation in 45%, and severe sepsis in 15% of patients. The incidence of acute GVHD grade II–IV was 25%, grade III-IV GVHD was 15%, and moderate chronic GVHD was 20%, with no severe cases. Only 2 patients required systemic steroids. Haematological relapse was documented in 1 patient. Two-year non-relapse mortality was 15%, 2-year overall survival was 85%, and 2-year event-free survival was 72%.

Conclusion

GVHD prophylaxis with PTCy and ruxolitinib is associated with low toxicity, good acute and chronic GVHD control, and low relapse incidence. However, the relatively high rate of SPGF should be taken into account. SPGF could possibly be mitigated by ruxolitinib dose reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationAdultCyclophosphamideDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansImmunosuppressive AgentsMaleMiddle AgedNitrilesPilot ProjectsPrimary MyelofibrosisProspective StudiesPyrazolesPyrimidinesRecurrenceSeverity of Illness IndexSurvival RateTransplantation, Homologous

Stichwörter der Autor:innen

Allogeneic stem cell transplantationMyelofibrosisPost-transplant cyclophosphamideRuxolitinib

Substanzen

Immunosuppressive AgentsNitrilesPyrazolesPyrimidinesruxolitinibCyclophosphamide

Autor:innen und Institutionen

  • R.M. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation.
  • R.M. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation, maria.barabanshikova.spb@gmail.com.
  • Nikiforov Russian Center of Emergency and Radiation Medicine, Saint-Petersburg, Russian Federation.
  • Laboratory of Autoimmune Diagnostics, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation.

Zitieren

APA

Morozova, E. V., Barabanshikova, M. V., Moiseev, I. S., Shakirova, A. I., Barhatov, I. M., Ushal, I. E., Rodionov, G. G., Moiseev, S. I., Surkova, E. A., Lapin, S. V., Vlasova, J. J., Rudakova, T. A., Darskaya, E. I., Baykov, V. V., Alyanski, A. L., Bondarenko, S. N., & Afanasyev, B. V. (2021). A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis. Acta Haematologica, 144(2), 158-165. https://doi.org/10.1159/000506758

Vancouver

Morozova EV, Barabanshikova MV, Moiseev IS, Shakirova AI, Barhatov IM, Ushal IE, et al. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis. Acta Haematologica. 2021;144(2):158-165. doi:10.1159/000506758

BibTeX
@article{Morozova2021,
  author = {Morozova, Elena Vladislavovna and Barabanshikova, Maria Vladimirovna and Moiseev, Ivan Sergeevich and Shakirova, Alena Igorevna and Barhatov, Ildar Munerovich and Ushal, Inna Edvardovna and Rodionov, Gennadij Georgievich and Moiseev, Sergey Ivanovich and Surkova, Elena Arkadjevna and Lapin, Sergey Vladimirovich and Vlasova, Julia Jurjevna and Rudakova, Tatjana Alexandrovna and Darskaya, Elena Igorevna and Baykov, Vadim Valentinovich and Alyanski, Alksandr Leonidovich and Bondarenko, Sergey Nikolaevich and Afanasyev, Boris Vladimirovich},
  title = {A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis},
  journal = {Acta Haematologica},
  year = {2021},
  volume = {144},
  number = {2},
  pages = {158--165},
  doi = {10.1159/000506758}
}
Kostenlos starten →